Because the mitotic gene signature correlated with TP53 and CTNNB1 gene mutations in HCC patients (Figure 3C,D), we hypothesized that HCC subtyping based on TP53 and CTNNB1 gene mutation statuses might exhibit a potential benefit from paclitaxel treatment. This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.